5-Year Safety Data From Upadacitinib Trials Reported

Upadacitinib trials in atopic dermatitis have included diverse patient groups with varying risk factors, according to Dr Christopher Bunick.

Related Keywords

Connecticut ,United States ,United Kingdom ,Yale University ,New Haven ,Denmark ,Danish ,Leo Pharma ,Eli Lilly ,Christopherg Bunick ,Upadacitinib Rinvoq ,Pfizer ,Novartis ,Drug Administration ,Revolutionizing Atopic Dermatitis Virtual ,Ortho Dermatologics ,Connect Bropharma ,Dermatitis ,Atopic Dermatitis ,Atopic Eczema ,Herpes Zoster ,Shingles ,Adolescent Medicine ,Teens ,Eenage ,Teenager ,Adolescent Health ,Adolescents ,Adolescent ,Cv Risk ,Cardiovascular Risk ,V Risk Factors ,Cardiovascular Risk Factors ,Cardiovascular Risk Management ,Body Mass Index ,Mi ,Clinical Research ,Clinical Trials ,Linical Studies ,Pre Clinical Trial ,Double Blind Study ,